Purpose The objective was to estimate health care costs and productivity losses due to epilepsy in Sweden and to compare these estimates to previously published estimates. Methods Register data on health care utilisation, pharmaceutical sales, permanent disability and mortality were used to calculate health care costs and costs that accrue due to productivity losses. By linkage of register information, we were able to distinguish pharmaceuticals prescribed against epilepsy from prescriptions that were prompted by other indications. Results The estimated total cost of epilepsy in Sweden in 2009 was €441 million, which corresponds to an annual per-patient cost of €8,275. Health care accounted for about 16% of the estimated total cost, and drug costs accounted for about 7% of the total cost. The estimated health care cost corresponded to about 0.2% of the total health care cost in Sweden in 2009. Indirect costs were estimated at €370 million, 84% of which was due to sickness absenteeism. Costs resulting from epilepsy-attributable premature deaths or permanent disability to work accounted for about 1% of the total indirect cost in Sweden in 2009. Discussion The per-patient cost of epilepsy is substantial. Thus, even though the prevalence of the illness is relatively small, the aggregated cost that epilepsy incurs on society is significant.
Introduction
The costs of epilepsy in Europe in 2004 have been estimated at €15.5 billion, comprising €2.8 billion in excess health care expenditures and €8.6 billion in reduced production of goods and services in the 25 EU member countries plus Iceland, Norway and Switzerland [9] . According to these estimates, health care expenditures attributed to epilepsy accounted for 0.2% of the total European national income in 2004. The annual cost per person diagnosed with epilepsy varied for the different countries included from €2,000 to €11,500; for Sweden, it was about €8,000. The great variance between countries in estimated cost may be explained by differences in the functioning of the health care sector, for instance as regards methods used for diagnosing epilepsy and the supply of health care for those diagnosed.
that use sub-populations seem to be the more prevalent. While bottom-up studies facilitate the gathering of detailed information regarding the utilisation of resources, such studies often rely on sub-samples of the population that are too small to be able to convey any significant information regarding the population as a whole. Moreover, most of the previous cost studies do not include production losses.
Pharmaceutical treatment is the main form of treatment used to prevent epileptic seizures. Thus, most previous studies include pharmaceutical costs. However, since several pharmaceuticals used against epilepsy have multiple indications and are therefore also prescribed for other diagnoses, the total utilisation of these pharmaceuticals cannot be attributed to epilepsy. In this study, we used individual register information, as regards total population prescribed amounts of pharmaceuticals and in-and outpatient care, in order to estimate the proportion of each antiepileptic pharmaceutical that is attributable to epilepsy. To the best of our knowledge, this is the first study to explore the possibilities offered by available registries in order to estimate shares of antiepileptic pharmaceuticals with multiple indications that have been prescribed due epilepsy.
Our overall objective was to estimate the cost of epilepsy in Sweden in 2009 and compare it to the total cost of all illnesses (in Sweden), using consistent methodology (prevalence-based top-down study), data and data collection. Thus, health care costs and productivity losses due to epilepsy were estimated, using data from Swedish public registers. Furthermore, our results were compared to recent studies of the cost of epilepsy in different European countries. We have, however, only been able to identify one previous peer-reviewed study of the cost of epilepsy in Sweden [11] , and one study of the cost of epilepsy in Europe [9] that includes costs calculated for Sweden.
Materials and methods
Our study followed established methodology (see, for instance, [1] [2] [3] ) when applying a prevalence-based approach and a top-down methodology to estimate the different cost components. The human capital approach was used in order to place a monetary value on lost productive life years and lost productivity due to sickness absenteeism, i.e., by applying lost gross annual income as the measure of lost production during a person year and per working day [8, 10] . In the prevalence approach, the estimated value of lost output in a specific year should ideally be based on the prevalence population of early retirees and on mortality in previous years (as the loss of production will occur in future years). No readily available data allowed this procedure, and hence, we followed established practice and converted incidence figures on newly granted disability pensions and mortality into approximately equivalent estimates of the prevalence costs by calculating the present value of future lost production. Below, we provide a brief description of applied Materials and methods. The collection and utilisation of data are described in Fig. 1 . A more comprehensive description can be found in the online supplement.
We estimated health care cost, losses of life years, and productivity losses by age group (\19, 20-64, 65C) and gender. Health care costs included hospital care, visits to hospital-based specialists (outpatient care), primary-care visits and pharmaceutical costs. Productivity losses included losses due to long-standing disability, premature mortality and sickness absenteeism. Appropriate ATC codes for pharmaceuticals classified as antiepileptic drugs (AEDs) were identified by two epileptologists (Källén and Lundgren, at Lund University Hospital, Sweden). As AEDs have multiple indications, and since morbidity-specific prescription data are not systematically collected in Sweden, the proportions of these drugs that could be attributed to epilepsy were estimated as follows: a pharmaceutical prescription was assumed to be due to epilepsy if the individual receiving the prescription also received, at one or several occasions during, and including, the years 1998-2005, inpatient and/or specialised outpatient treatment for (1) epilepsy (main diagnosis; ICD-10 codes: G40, G41) or (2) other diseases of the central nervous system known to cause symptomatic epilepsy were identified stroke, brain tumour or dementia (ICD-10 codes: C70, C71, D32, D33, I60-I69, and F00-F03). Moreover, since some patients with chronic epilepsy are known to be followed by their general practitioner (GP) in primary care and hence may not show up in the in-or outpatient care registries with an epilepsy, or epilepsy-related diagnosis [6] , we calculated the shares of the prescribed amounts of the six drugs that had no other indication than epilepsy-phenobarbiturate (in Sweden, epilepsy is the only indication for phenobarbiturate when prescribed in outpatient care), primidone, ethosuximide, vigabatrin, felbamate and levetiracetam-that could not be attributed to epilepsy according (1) and (2) above and that were prescribed in primary care by a GP. Adjoining these estimates with the previously calculated epilepsy-attributable shares, we obtained an upper boundary of the shares of prescriptions that can be attributed to epilepsy.
The number of (1) hospital admissions, (2) specialist and GP visits, (3) newly granted disability pensions and (4) deaths, due to epilepsy, were collected for 2005 and valued using 2009 (1) DRG unit costs for hospitalisation, (2) Skåne county-council unit costs for specialist and GP visits and (3) annual wages including labour taxes. As regards pharmaceuticals, the pharmaceutical utilisation cost in 2005 was adjusted to 2009 using the increase in price per defined daily dose for the ATC group N03.
Sensitivity analysis was performed regarding the effect of (1) shares of prescribed pharmaceuticals that can be attributed to epilepsy and (2) the discount rate used for calculating the present value of indirect costs on costs. Unit costs affect estimated total cost in a straightforward way: increasing a unit cost by X% means that the corresponding total cost would increase by the same (X) proportion.
Results
Calculated shares of the respective drugs included in the analysis that were attributed to epilepsy are presented in Table 1 . For the six AEDs that have no other indication than epilepsy, the shares of prescribed amounts made to patients that had not received in-or outpatient care due to epilepsy, which were made in primary care by GPs, and estimated total shares are presented in Table 2 . Adjusting for GP prescriptions, using these shares, produced the final estimates of shares prescribed due to epilepsy (in italics). In Table 3 , we present epilepsy-attributable monetary cost for each pharmaceutical included in the study. The entries in Tables 1, 2 and 3 are ordered according to ATC code, but we distinguish between firstand second-generation AEDs. Moreover, the number of (living) individuals identified was 53,674, corresponding to an epilepsy prevalence of about 0.6%, which is in accordance with the estimated epilepsy prevalence in Europe by [5] .
Summaries of the estimated economic impact of epilepsy, including health care costs, productivity losses, lost life years and lost productive years (due to mortality or permanent disability) are provided in Table 4 (total, per 100,000 inhabitants and per patient) and 3 (per patient and age group). Moreover, for comparison purposes, Table 4 also report the costs for all illnesses in 2009 calculated using the same methodology as for costs due to epilepsy.
The estimated total cost for epilepsy was € 441 million for 2009. This corresponds to € 4.91 million per 100,000 inhabitants or € 8,275 per person diagnosed with epilepsy. Health care costs accounted for 16% of the total cost in 2009 (indirect costs, premature mortality, permanent disability and sickness absenteeism, accounted for 84%), which corresponds to € 1,383 per person with diagnosed epilepsy in 2009. As compared to total costs for all illnesses in Sweden in 2009, health care costs due to epilepsy accounted for about 0.2% of total health care costs, while indirect costs (not including costs due to sickness absenteeism and formal care, which could not be estimated for all illness) accounted for about 1% of the total indirect cost.
Total per-patient costs per age group vary between, on the one hand, the youngest and the elderly, and those in working ages on the other. The direct cost estimates show that the per-patient cost is increasing with age, for both men and women. Patients in the oldest age group utilise more inpatient care and more pharmaceuticals compared to the younger patients. For details, see Table 5 .
The results of sensitivity analysis, with respect to the discount rate and shares of pharmaceutical prescriptions that can be attributed to epilepsy, are reported in Table 6 . The base case discount rate was 5%. If the 'true' discount rate was 2.5%, the estimated cost (due to productivity loss from premature mortality and permanent disability) would have been about 28% higher. If, on the other hand, the 'true' discount rate was 10%, the estimated cost would have been about 32% lower. Further, excluding symptomatic epilepsy as criteria for attributing prescriptions to epilepsy would have resulted in a 10% lower pharmaceutical cost and including also GP prescriptions in the criteria would have resulted in a 3% higher cost.
Discussion
In this register-based study, we estimated the per-patient cost for epilepsy in Sweden in 2009 at € 8,275, corresponding to a total cost of € 441 million. A comparison with previous studies-Silfvenius [11] and Pugliatti et al. [9] -shows that the annual increase in total cost was 0. 
Shares excluding diagnoses associated with symptomatic epilepsy are presented in italics for each group. Pharmaceuticals that are numbered are those that have epilepsy indications only: numbers 1-5 are older AEDs; 6 newer AED. Pharmaceuticals that have not been numbered have more than one indication. * Means that the pharmaceutical is a second-generation AED For each group, the left column shows shares of not-epilepsy-attributable prescriptions-according to the definition given above-that were prescribed by GPs in primary care
For instance, 38% of the amount of phenobarbiturate that was prescribed to men in the age group 20-64 was prescribed to patients that had not received hospital-based care due to epilepsy ( Table 1) . 74% of these prescriptions were due to epilepsy but performed by GPs. Thus, the 90% reported below was calculated as 62% ? 0.74 9 38% = 90%. The column to the right summarises estimated total shares identified from hospital-based care and GP prescriptions. * Means that the pharmaceutical is a second-generation AED Per-patient pharmaceutical costs due to epilepsy were estimated, for 1975, at € 202 by Silfvenius [11] and for 2004, at € 510 by Pugliatti et al. [9] . Neither of these previous estimates considered that several AEDs have more than one indication and may, hence, have been prescribed for a range of conditions other than epilepsy. Furthermore, the per-patient pharmaceutical cost assumed in the Pugliatti study stems from pharmaceutical sales in 2000 and did not include phenobarbiturate, primidone, ethosuximide, clonazepam and pregabalin. Thus, even though the per-patient pharmaceutical cost calculated in this study takes into account that AEDs may be used against other illnesses than epilepsy, we arrived at a higher per-patient cost-€ 569. This figure is considerably higher than the Silfvenius [11] figure, which, no doubt, can be explained by the increase in the number of available antiepileptic pharmaceuticals since 1975, and that the costs for newer AEDs are substantially higher compared to the old generation pharmaceuticals. From Table 3 , it can be inferred that about 78% of the total pharmaceutical cost in 2009 were due to the utilisation of second-generation AEDs.
Further, the productivity losses resulting from premature deaths calculated in this study exceed both the losses in 1975 and the losses in 2004 reported by Pugliatti et al. [9] -€ 727 per patient in our study versus € 417 and € 352, respectively. These differences are caused mainly by increased productivity, which means that larger expected losses occur for each premature death. However, there are reasons to believe that the 'true' difference between our study and, in particular, the Silfvenius [11] study is much smaller. Sudden, unexpected death in epilepsy, one of the main causes of premature mortality (before 65 years of age) among epilepsy patients, was previously underrecognised as being caused by epilepsy [13] . However, during the time period studied the awareness of risks associated with epilepsy has improved, resulting in reduced under-diagnosis of deaths as being caused by epilepsy. Thus, the reported average number of deaths in Sweden caused by epilepsy during the years 1971-1984 is likely to significantly underestimate the 'true' mortality due to epilepsy.
We derived the estimates of epilepsy-attributable shares of prescribed AEDs using joint information regarding prescriptions and health care utilisation for patients with a main diagnosis of either epilepsy or some other disease(-s) known to cause symptomatic epilepsy. For AEDs that have epilepsy as the only indication, we performed an additional analysis by including also GP prescriptions for patients that Epilepsy: the cost-of-illness 823
could not be identified as having epilepsy from their health care utilisation. Thus, we obtained estimated epilepsyattributable shares for these AEDs in the region of 80-90% in the adult population. The differences between the estimated 80-90% shares and total prescriptions are likely to be due to imperfections in the data. For instance, (1) the coding, on the one hand, of the in-and outpatient registries and, on the other hand, the pharmaceutical registry is performed by different administrative bodies, and (2) about 25% of all hospital-based specialist outpatient visits have no main diagnosis. However, for the youngest age group (0-19), the proportion of prescribed single-indication AEDs that could not be attributed to epilepsy remain high even after 'controlling' for symptomatic epilepsy and GP prescriptions. In particular, for phenobarbiturate and primidone, the estimated shares are in the region of 56-78%, including the adjustment obtained from GP prescriptions. There may be several reasons for this, for instance, infants with symptomatic epilepsy having other main diagnoses at hospital in-care periods than the adult population (such as mental retardation, cerebral paresis or chromosomal or metabolic syndromatic disorders). Additional methodological differences between our study and the Pugliatti et al. study concern the sources of information and included cost components. The Pugliatti study (1) employed bottom-up information on per-patient cost components in order to approximate the total cost of epilepsy, while our study employed a top-down approach, (2) included both direct and indirect cost components other than those included in our study. More specifically, we did not-due to the lack of information-estimate costs associated with support service and informal care. Further, the The table reports on unit costs and calculated costs
Costs are reported both as physical quantities (utilisation) and in monetary terms, as total costs and per 100,000 inhabitants and per patient. Loss of productivity was discounted at 5%. Monetary costs in bold; total monetary costs in bold italic. Sums contain rounding errors * Administrative registry of Region Skåne methodology adopted by Silfvenius differs from ours when computing the cost of epilepsy in Sweden by applying US population prevalence of epilepsy, and Swedish treatment costs pertaining to 'diseases of the nervous system', rather than epilepsy. A more elaborate account of the methodological differences can be found in the online supplement. The table reports per-patient utilisation and total cost (€), per age group and gender. Loss of productivity discounted at 5% Lastly, our approach utilised main diagnoses and, hence, did not distinguish between resources used due to epilepsy and resources used due to co-morbidities for a particular hospital visit or stay. Thus, to the extent that epilepsy patients receive care, due to other health conditions than epilepsy during a hospital episode with epilepsy as corresponding main diagnosis, our estimates overestimate the true health care costs.
In conclusion, this study has shown that the total costs of epilepsy, including pharmaceutical costs, is considerable even when controlling for the fact that the drug used may have several indications. Previous studies have not taken this into consideration. Nonetheless, the pharmaceutical cost estimated in this study is higher than the corresponding estimates for both 1975 and 2004, suggesting that the true increase in epilepsy-attributable pharmaceutical cost has increased more sharply than reflected by the reported figures. Moreover, our results, when compared to the calculations performed by Silfvenius, suggest that improvement in health care has reduced the indirect costs associated with epilepsy. However, the knowledge as regards indirect costs induced by temporary and permanent morbidity is still limited. Future studies that shed light on this are needed.
